olaparib,abiraterone
merck,astrazeneca,janssen
[' ola ', 'biomarker', 'propel', 'brca', 'crpc', 'medsir', 'marker ']
updated results of phase 3 propel trial presented by #fredsaad show a continuing trend towards improved os with abi + ola vs. abi + pbo in pts with mcrpc, and a meaningful rpfs improvement of 5 months in all assessed biomarker subgroups (non-hrrm, hrrm, brcam status). #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM